Provided by Tiger Trade Technology Pte. Ltd.

Nuo Therapeutics, Inc.

1.30
0.0000
Volume:- -
Turnover:- -
Market Cap:62.96M
PE:-31.06
High:1.30
Open:1.30
Low:1.30
Close:1.30
52wk High:2.92
52wk Low:0.7700
Shares:48.43M
Float Shares:23.46M
Volume Ratio:1.18
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0419
EPS(LYR):-0.0293
ROE:-1032.50%
ROA:-54.33%
PB:-41.01
PE(LYR):-44.44

Loading ...

Sep 19, 2024

Major Issues Report

Form 8-K - Current report
Aug 12, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jun 27, 2024

Major Issues Report

Form 8-K - Current report
Jun 11, 2024

Major Issues Report

Form 8-K - Current report
May 21, 2024

Major Issues Report

Form 8-K - Current report
May 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 19, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Apr 16, 2024

Major Issues Report

Form 8-K - Current report
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Dec 21, 2023

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Dec 20, 2023

Major Issues Report

Form 8-K - Current report
Nov 21, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 14, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 03, 2023

Major Issues Report

Form 8-K - Current report
May 16, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 18, 2023

[Rev.]Annual Report

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
Apr 17, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Dec 05, 2022

Major Issues Report

8-K - Current report
Nov 04, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]